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Abstract Fluorouracil (5-FU) remains the most widely
used agent for colorectal cancer. Capecitabine is a ratio-
nally designed 5-FU pro-drug developed to mimic the
continuous infusion of 5-FU while avoiding complications
and inconvenience of intravenous administration. Cape-
citabine is absorbed intact from the gastrointestinal tract,
converted enzymatically to active 5-FU, and released
directly into the tumor. Capecitabine’s efficacy and safety
are shown in multiple phase III trials across different dis-
ease stages and therapy lines. Three randomized phase III
trials demonstrated the equivalence of capecitabine plus
oxaliplatin (XELOX) versus 5-FU/leucovorin (LV)/oxa-
liplatin (FOLFOX). The safety of capecitabine compared
with 5-FU depends on the regimen of 5-FU used. The
adverse event rate with oxaliplatin in combination with
infusional 5-FU is similar to that of capecitabine plus
oxaliplatin but is associated with more neutropenia and
venous thrombotic events; capecitabine plus oxaliplatin-
based regimens tend to be associated with more grade 3
diarrhea and hand-foot skin reaction. Combination therapy
with capecitabine and irinotecan (CapeIRI) versus 5-FU/
LV and irinotecan (FOLFIRI) had more variable results;
some former schedules resulted in excessive treatment-
related toxicity. More recent data show that lower cape-
citabine and irinotecan doses, different schedules, and
combination with targeted agents (e.g, bevacizumab) have
resulted in more favorable outcomes.
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Introduction
The most widely used agent in the treatment of colorectal
cancer (CRC) is fluorouracil (5-FU), which was developed
more than 50 years ago by Heidelberger et al. [1]. 5-FU
enters a complex anabolic process that interferes with
normal DNA and RNA functions and accounts for cyto-
toxicity at the cellular level. Because of poor oral absorp-
tion and intra-patient variability, 5-FU is most often
administered intravenously (IV) as a rapid bolus injection;
it is rapidly distributed, with triphasic elimination [2].
Preclinical studies suggested that 5-FU is a time-dependent
drug, and that cytotoxicity increases with prolonged
exposure [2–4]. Therefore, clinical trials were initiated
with 5-FU administered for extended periods [5, 6].
Response rates in CRC increased with continuous infusion
compared with bolus administration, with a more accept-
able toxicity profile [7, 8]. Nevertheless, the inconvenience
of protracted IV administration provided a strong impetus
for the development of oral fluoropyrimidines that could be
taken conveniently on a schedule that simulates continuous
infusion [9].
Capecitabine is an example of a rationally designed
5-FU pro-drug intended to mimic the continuous infusion
of 5-FU while avoiding the complications and inconve-
nience associated with IV drug administration. It is a flu-
oropyrimidine carbamate that is converted to the active
5-FU by the action of three enzymes: an esterase, a
deaminase, and a phosphorylase [9]. In the third step, the
enzyme thymidine phosphorylase (TP) converts 50-deoxy-
5-fluorouridine to 5-FU, which is released directly into
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tumor tissue [10]. The enzyme TP has higher concentra-
tions in many tumor types compared with matched normal
tissue and is particularly higher in excised human colon
cancer [11]. This suggests that higher tumor concentrations
of 5-FU might be expected, due to a higher production of
active drug in the tumor tissue, thereby providing a
favorable target-to-non-target ratio for toxicity. Tumor
selectivity and conversion of capecitabine to active 5-FU
within the tumor tissue have been confirmed in human
samples that show a 3.2-fold higher concentration of 5-FU
in tumor compared with normal tissue and a 21-fold higher
tumor-to-plasma ratio. In comparison, when IV 5-FU is
administered, either by bolus or continuous infusion, the
concentration of active drug in tumor is not higher than that
in normal tissue [11]. The greater levels of the TP enzyme
in tumor tissue allow for targeted intra-tumoral release of
5-FU and subsequently less systemic toxicity compared
with infusions of 5-FU [12].
This review provides an up-to-date literature review and
overview of how capecitabine compares with 5-FU as a
single agent as well as in combination with oxaliplatin or
irinotecan, and in combination with targeted therapy, in the
treatment of CRC. We review the available phase I, II,
and III clinical trials conducted in patients with CRC that
document the metabolic activation of this compound and
support its use in patients with advanced CRC and how the
drug may be incorporated into the standard care of patients
with CRC.
Clinical efficacy and tolerability
Various schedules of single-agent capecitabine were
tested in three phase I trials (Table 1). These trials revealed
that intermittent dosing allowed for higher doses of
capecitabine but at the expense of increased hand-foot
syndrome (HFS). Diarrhea was the dose-limiting toxicity in
all treatment schedules [13–15]. A randomized phase II
trial was performed to further define activity and the
optimum schedule to carry forward into phase III trials. In
this study, metastatic CRC (mCRC) patients were ran-
domized between the three leading schedules of capecita-
bine [continuous, intermittent, or intermittent with
leucovorin (LV)]. No difference in overall survival (OS)
was noted between the arms; however, significant
improvement in disease progression was observed for the
single-agent intermittent schedule. The intermittent sche-
dule without LV was recommended for phase III study
based on its improved progression-free survival (PFS), the
high dose intensity, and better therapeutic index [16].
Capecitabine as a single agent
Two multicenter, randomized, phase III studies were con-
ducted (1 in North America, 1 in Europe) comparing cape-
citabine with IV 5-FU/LV as first-line therapy in metastatic
CRC patients. The trials were identical with respect to study
design, inclusion and exclusion criteria, primary end point of
overall response rate (RR), and secondary end points such as
median time to disease progression, median time to treatment
failure, and OS times, in order that subsequent pooling of
results could be performed (Table 2) [17–19].
Patients were randomly assigned to either capecitabine
in an intermittent regimen of 3-week cycles or 5-FU/LV,
administered according to the Mayo Clinic regimen (5-FU
425 mg/m2 plus LV 20 mg/m2 administered IV for 5 days
every 28 days). The Mayo Clinic regimen was chosen as a
control arm for both studies, as it was the standard of care
for front-line therapy of mCRC at the time of trial design
[17, 18].




Regimen Response Safety, tolerability
Budman et al.
[13]
33 110–1,675 mg/m2/day continuously
in two equally divided doses;
1,331 mg/m2 established as phase
II dose
One patient with a mixed response;
one with SD after 18 months of
therapy




34 502–3,414 mg/m2/day in two equally
divided doses for 14 days followed
by 7 days’ rest; 2,510 mg/m2/day
recommended as phase II dose
Objective tumor response in five
patients at 2,510 mg/m2; one CR
and three PRs




31 1,004–2,510 mg/m2 ? LV 60 mg bid
for 14 days followed by 7 days’ rest;
1,650 mg/m2/day C ? 60 mg LV
recommended as phase II dose
Two PRs Dose-limiting AEs at 2,000 mg/
m2/day included nausea,
diarrhea, vomiting, and HFS
AEs adverse events, bid twice a day, C capecitabine, CR complete response, HFS hand-foot syndrome, LV leucovorin, PRs partial responses,
SD stable disease
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In both studies, RRs were higher for capecitabine
compared with 5-FU/LV: 25.8 versus 11.6% (P = 0.005)
and 18.9 versus 15%, respectively. Although capecitabine
demonstrated higher RRs, median time to disease pro-
gression and median OS did not differ significantly
between the arms in both studies. Compared with the 5-FU/
LV group, patients in the capecitabine group experienced a
significantly lower incidence of any grade diarrhea, sto-
matitis, nausea, and alopecia, but a higher incidence of
HFS and hyperbilirubinemia [19]. These trials demon-
strated that capecitabine monotherapy is a reasonable
alternative for patients with mCRC.
Capecitabine in combination with oxaliplatin
or irinotecan
The combination of the cytotoxic agents oxaliplatin and
irinotecan, and targeted agents such as cetuximab, pani-
tumumab, and bevacizumab with 5-FU, have significantly
improved survival rates for patients with mCRC and are
now the standard of care. Therefore, based on similar
efficacy and reduced toxicity compared with bolus 5-FU
regimens, capecitabine was tested in combination with the
cytotoxic agents oxaliplatin and irinotecan.
Preclinical models have demonstrated that the combi-
nation of capecitabine and oxaliplatin is a rational combi-
nation therapy for the treatment of CRC. In a human tumor
xenograft model, the combination of capecitabine and
oxaliplatin inhibited the in vivo growth of CXF280 human
CRC more effectively than either agent alone [20].
A phase I study in patients with metastatic solid tumors
demonstrated that the combination of capecitabine with
oxaliplatin is feasible and established the recommended
dose regimen as IV oxaliplatin 130 mg/m2 on day 1, with
oral capecitabine 1,000 mg/m2 twice daily on days 1–14 in
a 3-week cycle [21]. When this regimen was evaluated in a
phase II study in patients with mCRC, the RRs ranged
between 45 and 55%, with sensory neuropathy (17%),
diarrhea (16%), and nausea and vomiting (13%) as the
most common treatment-related adverse events (AEs) [22].
Three randomized phase III studies, one of which was
published only in abstract form, demonstrated the equiva-
lence of capecitabine with oxaliplatin (XELOX) in com-
parison with 5-FU/LV/oxaliplatin (FOLFOX) as first- and
second-line therapy of mCRC (Table 3) [23–25]. Patients
were randomly assigned to a regimen of XELOX or
FOLFOX-4.1 These trials demonstrated that XELOX is
equivalent to FOLFOX with respect to PFS when used as
first- or second-line therapy in patients with mCRC.
Treatment-related grade 3/4 AEs such as neutropenia/
granulocytopenia (35 vs. 5%) and febrile neutropenia (4 vs.
\1%) were more frequent with FOLFOX-4 than with
XELOX, though grade 3 diarrhea (19 vs. 5%) and HFS
(4 vs.\1%) were higher for the XELOX regimen [23–25].
A pooled analysis of six randomized phase II/III trials
evaluating the role of oxaliplatin in combination with
capecitabine or infusional 5-FU included 3,494 patients
with mCRC and demonstrated similar PFS and OS in
patients treated with the two regimens. However, patients
treated with XELOX had lower RRs. In this review,
FOLFOX demonstrated a statistically significant RR of
41–52% as compared to XELOX, with an RR of 27–48%
(P = 0.02) [26]. Thus, the use of XELOX is a valid
alternative regimen for patients with mCRC.
Capecitabine in combination with irinotecan was
extensively studied in a wide range of schedules in













605 1,250 mg/m2 bid for 14 days












Lower rate of diarrhea,
stomatitis, nausea, and
alopecia with C vs. 5-FU;
higher rate of HFS and
hyperbilirubinemia
with C vs. 5-FU
Van Cutsem
et al. [18]
602 1,250 mg/m2 bid for 14 days











Lower rate of diarrhea,
stomatitis, nausea, and
alopecia with C vs. 5-FU;
higher rate of HFS and
hyperbilirubinemia
with C vs. 5-FU
Bid twice a day, C capecitabine, 5-FU fluorouracil, HFS hand-foot syndrome, LV leucovorin
1 FOLFOX-4 = oxaliplatin 85 mg/m2 on day 1 only given as a 2-hour
infusion concurrent with LV at 200 mg/m2/d followed by bolus 5-FU
400 mg/m2/d and a 22-hour infusion of 5-FU 600 mg/m2/d, repeated
for 2 consecutive days every 2 weeks.
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different regimens (i.e., 2-weekly, 3-weekly, 4-weekly,
6-weekly, and 7-weekly) [27–30]. Reports of excessive and
overlapping toxicities, specifically of gastrointestinal ori-
gin, prompted alterations in the dose and administration
schedule. Promising results were demonstrated from a
phase II trial evaluating capecitabine in combination with
irinotecan administered every 2 weeks. This trial demon-
strated a median time to progression of 8.4 months, a
median duration of response of 7.3 months, and an OS of
19.3 months (Table 4) [30].
The BICC-C (Bolus, Infusional, or Capecitabine with
Camptosar-Celecoxib), a randomized phase III trial
explored three combinations of irinotecan-based regimens.
In this study, 430 previously untreated mCRC patients
randomized to FOLFIRI (irinotecan plus infusional 5-FU/
LV), mIFL (irinotecan plus bolus 5-FU/LV), or CapeIRI
(irinotecan plus capecitabine), all in combination with
celecoxib (Table 4) [27]. The CapeIRI arm was discon-
tinued early in the trial because of unacceptable toxicity. In
addition, the trial was amended to add bevacizumab to the
FOLFIRI and mIFL arms. Adding bevacizumab improved
PFS for both FOLFIRI and mIFL, from 7.6 to 11.2 months
and from 5.9 to 8.3 months, respectively. The OS for the
FOLFIRI and bevacizumab arm was 23.1 months. Inferior
efficacy results for CapeIRI might reflect early treatment
discontinuation as a result of toxicity, or an interaction with
celecoxib [27].
EORTC 40015 compared FOLFIRI and CapeIRI in 85
patients in the second line setting for mCRC. There was
sub-randomization to celecoxib versus placebo, and med-
ian PFS and OS times were shorter for CapeIRI versus
FOLFIRI and for celecoxib versus placebo. The trial was
closed early following 8 deaths in the 85 patients enrolled,
mostly related to gastrointestinal or thromboembolic
events, but not related to disease progression. Given the
small number of patients and early closure of the study, it is
hard to draw meaningful conclusions [28]. Another phase
III trial evaluating sequential chemotherapy versus initial
combination chemotherapy with CapeIRI demonstrated a
longer PFS for the combination regimen at the expense of
Table 3 Capecitabine and oxaliplatin
References Study phase,
patients enrolled










XELOX (2-h IV infusion Ox
130 mg/m2 on day 1 ? C
1,000 mg/m2 bid on days
1–15 of a 3-week cycle) or
FOLFOX-4 (Ox 85 mg/m2
on day 1 as a 2-h infusion
concurrent with LV
200 mg/m2/day followed
by bolus 5-FU 400 mg/m2/




















Grade 3/4 AEs: 65 vs. 50%;
grade 4 AEs: 18 vs. 3%;
febrile neutropenia: 4 vs.
\1%; grade 3 diarrhea:






XELOX OR FOLFOX-4 B at
7.5 mg/kg or PBO added to
XELOX every third week
and B at 5 mg/kg or PBO
















Rates of grade 3/4 AEs
similar in both arms; grade
4 AEs more common with
FOLFOX-4 due to grade 4
neutropenia. XELOX
associated with more grade




N = 306 (ITT);
N = 284 (PP)
XELOX OR FOLFOX-6
(Ox 100 mg/m2 day, LV
400 mg/m2 2-h infusion,
then 5-FU 400 mg/m2 IV
bolus, then
2,400–3,000 mg/m2 46 h
infusion) every 2 weeks for
6 months











Grade 3/4 HFS: 3 vs. 0%;
thrombocytopenia: 12 vs.
5%; diarrhea: 12 vs. 7%;
grade 3/4 neutropenia: 0 vs.
6%; neuropathy: 8 vs. 19%
(XELOX vs. FOLFOX-6)
AEs adverse events, B bevacizumab, bid twice a day, C capecitabine, 5-FU fluorouracil, FOLFOX fluorouracil/leucovorin/oxaliplatin, HFS hand-foot
syndrome, ITT intent-to-treat, IV intravenous, LV leucovorin, Ox oxaliplatin, ORR overall response rate, PBO placebo, PP per protocol, XELOX
capecitabine plus oxaliplatin
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greater toxicity [29]. Capecitabine and irinotecan combi-
nations have similar activity as 5-FU and irinotecan regi-
mens, but greater toxicity. Further studies to determine the
most appropriate dose of capecitabine in combination with
irinotecan and in other combination regimens for particular
geographic and/or ethnic patient groups may be warranted.
Combination chemotherapy with targeted agents such
as bevacizumab or cetuximab
Targeted therapies with vascular endothelial growth factor
(VEGF) inhibitors such as bevacizumab, and epidermal
growth factor receptor (EGFR) inhibitors such as cetux-
imab or panitumumab, have become a significant part of
the management of mCRC.
VEGF is the central regulator of angiogenesis. In recent
years, considerable interest has developed regarding the
importance of angiogenesis in tumor growth and progres-
sion [31]. Increased expression of VEGF in patients with
colorectal carcinoma has been associated with early
recurrence and poor prognosis [32]. In randomized phase
III clinical trials in patients with mCRC, bevacizumab
improved RRs, OS, and PFS when combined with standard
chemotherapies such as infusional 5-FU/LV plus irinotecan
and FOLFOX [33, 34].
Given the improvement seen with addition of bev-
acizumab to 5-FU-containing regimens, new studies were
designed to evaluate the combination of bevacizumab- and
capecitabine-containing regimens. Results of the Three
Regimens of Eloxatin Evaluation (TREE)-2 trial provided
further evidence of increased efficacy when bevacizumab
was added to oxaliplatin-based chemotherapeutic agents
[35]. The TREE-1 and TREE-2 trials were sequentially
conducted, randomized, phase II trials that initially tested
three different oxaliplatin–fluoropyrimidine combination
regimens. These included FOLFOX, oxaliplatin plus bolus
5-FU/LV (bFOL), or capecitabine plus oxaliplatin
(CapeOx) as first-line treatment of advanced CRC. After
bevacizumab was approved in 2004, the trial was amended
to include bevacizumab in all arms. The addition of
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Grade 3/4 toxicity greater
in combination than
sequential arm; diarrhea:
26 vs. 11%; grade 3/4









Irinotecan 175 mg/m2 on
day 1 ? C 1,000 mg/m2
bid on days 2–8, repeated
every 14 days
CR: 7.5%; PR: 32%;








AEs adverse events, B bevacizumab, C capecitabine, CapeIRI capecitabine and irinotecan, CR complete response, FOLFIRI fluorouracil/
leucovorin/irinotecan, 5-FU fluorouracil, HFS hand-foot syndrome, LV leucovorin, mIFL irinotecan plus bolus fluorouracil/leucovorin, NS not
significant, ORR overall response rate, OS overall survival, Ox oxaliplatin, PBO placebo, PD progressive disease, PFS progression-free survival,
PR partial response, SD stable disease, TTP time to progression
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bevacizumab lengthened OS in the three different regi-
mens, as seen in TREE-2 compared with TREE-1
(Table 5). In the final toxicity analysis of TREE-2, bFOL
appeared to have the greater toxicity: efficacy ratio, with a
30% incidence of grade 3/4 diarrhea; for FOLFOX, the
incidence was 11% and for CapeOx, 17%.
Similarly, as previously discussed, the BICC-C trial also
has demonstrated benefit with the addition of bevacizumab
to chemotherapy [27]. In another phase III trial, addition of
bevacizumab to an oxaliplatin-based regimen such as
XELOX or FOLFOX-4 demonstrated improvement in PFS
(9.4 vs. 8 months; P = 0.0023) with no difference in RRs
and OS [36]. ACCORD is a prospective, non-comparative
phase II study randomizing 145 patients to XELIRI
(capecitabine/irinotecan), or FOLFIRI plus bevacizumab.
The study demonstrated a 6-month objective RR of 54% in
the XELIRI arm and 59% in the FOLFIRI arm. Median
PFS was 9.3 and 9.0 months, respectively, and median OS
was 23.0 and 23.4 months, respectively, in the XELIRI and
FOLFIRI arms. Clinical AEs generally were similar,
acceptable, and manageable in both treatment arms. This
randomized, non-comparative trial demonstrated that bev-
acizumab plus XELIRI and bevacizumab plus FOLFIRI are
active and similarly effective treatment options for patients
with mCRC [37].
Although adding bevacizumab therapy appears to
improve multiple efficacy points compared with cytotoxic
therapy alone, it is important to remember that the use of
bevacizumab with capecitabine combinations is based on
retrospective, cross-trial comparisons and phase II trial
data, but should be validated further in randomized phase
III trials.
Table 5 Capecitabine with bevacizumab
References Study phase,
patients enrolled









Phase III; N = 829 FOLFOX-4 with B;
FOLFOX-4; B alone




























N = 150; TREE-
2, N = 223;
Primary end
point = grade 3/4
AEs
TREE 1: modified
FOLFOX-6 (Ox 85 mg/
m2 IV ? LV 350 mg IV
over 2 h ? 5-FU 400 mg/
m2 IV bolus ? 2,400 mg/
m2 infusion over 46 h)
every 2 weeks or bFOL
(Ox 85 mg/m2 IV on days
1 and 15 ? LV 20 mg/m2
IV over 10–20 min
followed by 5-FU
500 mg/m2 IV push on
days 1, 8, and 15 every
4 weeks) or CapeOx (Ox
130 mg/m2 IV on day 1
and C 1,000 mg/m2 orally
bid on days 1–15 every
3 weeks TREE-2: same 3
arms ? B before CT at
5 mg/kg IV every
2 weeks (FOLFOX and
bFOL regimens) or
7.5 mg/kg IV every
3 weeks (CapeOx); C
dose reduced to
1,700 mg/m2/day





















TREE-1: Grade 3/4 AEs








TREE-2: 59, 51, 56%
(modified FOLFOX-6,
bFOL, CapeOx)
FOLFOX-4 = oxaliplatin 85 mg/m2 on day 1 only given as a 2-h infusion concurrent with LV at 200 mg/m2/day followed by bolus 5-FU 400 mg/m2/day
and a 22-h infusion of 5-FU 600 mg/m2/day, repeated for two consecutive days every 2 weeks; FOLFOX-6 = oxaliplatin 100 mg/m2 on day 1, LV
400 mg/m2 2-h infusion, then 5-FU 400 mg/m2 IV bolus, then 2,400–3,000 mg/m2 46-h infusion, every 2 weeks
AEs adverse events, B bevacizumab, bFOL oxaliplatin plus bolus 5-FU/LV, C capecitabine, CapeOx capecitabine plus oxaliplatin, CT chemotherapy,
FOLFOX fluorouracil/leucovorin/oxaliplatin, IV intravenous, LV leucovorin, ORR overall response rate, Ox oxaliplatin, TREE Three Regimens of Eloxatin
Evaluation
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EGFR gene is upregulated in 60–80% of CRC patients,
and over expression of the gene is associated with poor
survival. EGFR signaling pathways play a major role in
cell differentiation, proliferation, migration, angiogenesis,
and apoptosis. Two EGFR-directed antibodies have been
approved for the treatment of patients with advanced
colorectal carcinoma: cetuximab, a chimeric antibody, and
panitumumab, a fully humanized monoclonal antibody
[38, 39]. Phase III, CRYSTAL trial (Cetuximab Combined
with Irinotecan in First-Line Therapy for Metastatic
Colorectal Cancer) demonstrated improvement in PFS (8.9
vs. 8 months) and RR (46.9 vs. 38.7%) with addition of
cetuximab to irinotecan in front-line setting [40]. Only
improvement in RRs (22.9 vs. 10.8%) were noted in the
second-line setting based on phase III data by Cunningham
et al. [38]. Similarly, improvement in RR (45.6 vs. 35.7%)
was noted with the addition of cetuximab to FOLFOX in a
phase II OPUS (Oxaliplatin and Cetuximab in First-Line
Treatment of mCRC) trial [41].
Borner et al. conducted a multicenter, randomized,
phase II study comparing XELOX with the combination of
XELOX plus cetuximab. This trial demonstrated an increase
in RRs without a significant increase in toxicity, except for an
increased frequency of skin toxicity in the arm with cetux-
imab. Treatment was continued up to a maximum of six cycles
or until disease progression (Table 6) [42].
To date, there are limited published data on the XELIRI/
cetuximab regimen. Preliminary results from two phase II
trials of combinations of cetuximab with irinotecan plus
capecitabine demonstrate that this combination has prom-
ising clinical activity. Heinemann et al. have demonstrated
an overall RR of 42%, with an overall disease control rate
of 91% (Table 6) [43, 44]. Cartwright et al. [45] have
demonstrated in 53 evaluable patients that 5.7% had
complete responses, 37.7% had partial responses, and
43.4% had stable disease with median survival of
20.5 months, with 45.7% of patients remaining alive at the
time of the report (Table 6).
Although we are optimistic that cetuximab with a
XELOX or XELIRI combination will prove to be benefi-
cial, we await the results of ongoing phase III trials before
routinely applying these phase II results.
Table 6 Capecitabine with EGFR inhibitors
References Study phase,
patients enrolled









Phase II, N = 74 Ox 130 mg/m2/day ? C
1,000 mg/m2 bid days 1–14
every 3 weeks alone
(XELOX) or XELOX ? C
400 mg/m2 followed by
weekly infusions of
250 mg/m2

















Phase II, N = 92 C 800 mg/m2 bid on days
1–14 ? irinotecan 200 mg/
m2 on day 1 (XELIRI) or C
1,000 mg/m2 bid days
1–14 ? Ox 130 mg/m2 on
day 1 (XELOX)
ORR: 42 vs. 66%; DCR
















Phase II, N = 70;
53 evaluable
C 850 mg/m2 bid on days
1–14 for
3 weeks ? irinotecan
200 mg/m2 IV on day 1
every 3 weeks or C
850 mg/m2 bid on days
1–14 for
3 weeks ? irinotecan
200 mg/m2 IV on day 1
every 3 weeks ? C
(initially 400 mg/m2 IV,
subsequently 250 mg/m2
CR: 5.7%; PR: 37.7%;













C capecitabine, CR complete response, DCR disease control rate, EGFR epidermal growth factor receptor, ITT intent-to-treat, IV intravenous, ORR overall
response rate, Ox oxaliplatin, PP per protocol, PR partial response, RR response rate, SD stable disease, TTP time to progression, TTR time to response,
XELOX capecitabine plus oxaliplatin
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Capecitabine in the adjuvant setting
The benefits of 5-FU-based adjuvant chemotherapy in
reducing the risk of relapse and prolonging survival in
patients with surgically resected CRC are well established,
particularly in stage III disease [46–54]. In a phase III trial
[Xeloda in Adjuvant Colon Cancer Therapy (X-ACT)],
capecitabine was compared to Mayo Clinic 5-FU/LV reg-
imen as surgical adjuvant treatment in stage III CRC
(Table 7) [55]. Initially, there was a trend toward superior
disease-free survival (DFS) noted for the capecitabine arm
compared to 5-FU/LV (P = 0.05). However, the difference
did not hold true at the 3-year follow-up with loss of sta-
tistical difference between the arms (64.2 vs. 60.6%;
P = 0.12). Relapse-free survival was longer for the cape-
citabine arm as compared to 5-FU/LV (P = 0.04), though
OS did not differ significantly (P = 0.07). Overall, there
was a significantly lower incidence of neutropenia and
stomatitis and lower rates of nausea, vomiting, alopecia,
and diarrhea in the setting of adjuvant treatment with
capecitabine. However, the incidence of grade 3 HFS was
significantly higher with capecitabine than with 5-FU/LV.
This trial demonstrates that capecitabine is at least equiv-
alent to the Mayo Clinic regimen of 5-FU/LV in the sur-
gical adjuvant treatment of CRC [55].
The success of multiagent combination therapy in the
treatment of mCRC has provided a compelling basis for
testing such regimens in the adjuvant setting. Two large
trials have demonstrated that the addition of oxaliplatin to
5-FU/LV has been shown to prolong DFS significantly in
patients with stage II/III CRC, with a reduction in the risk
of recurrence of 23% in the group given 5-FU/LV plus
oxaliplatin compared with 5-FU/LV alone [56, 57].
These developments led to an international, randomized,
phase III trial (XELOXA) in which 1,886 patients were
randomized to adjuvant treatment with either XELOX or
IV bolus 5-FU/LV given by 1 of 2 regimens (Mayo Clinic
or Roswell Park). Bolus 5-FU/LV was chosen for com-
parison as it was standard at the time of study initiation.
Both safety and efficacy were assessed in this study, though
efficacy data were reported only in an abstract form indi-
cating a benefit in DFS for XELOX [58].
Most treatment-related AEs occurred at similar rates in
both treatment arms. However, patients receiving capecit-
abine plus oxaliplatin experienced less all-grade diarrhea
and alopecia, and more neurosensory toxicity, vomiting,
and HFS than with 5-FU/LV. Compared with the Mayo
regimen, capecitabine plus oxaliplatin demonstrated fewer
grade 3/4 hematologic AEs and more grade 3/4 gastroin-
testinal AEs. Compared with the Roswell Park regimen,
Table 7 Capecitabine in the adjuvant setting







N = 1,987 with
resected stage III
CRC
C 1,250 mg/m2 bid on days 1–14
every 21 days or six cycles of
rapid IV infusion of LV 20 mg/
m2 followed immediately by IV
bolus of 5-FU 425 mg/m2 on














nausea, vomiting, alopecia, and





N = 1,864 (safety
population) who
have undergone
surgery for stage III
colon carcinoma
XELOX (IV Ox ? C, 3-week
cycle for 8 cycles) or IV bolus
5-FU/LV administered as Mayo
Clinic or RP
Similar rates in both arms;
XELOX patients had less
diarrhea and alopecia; more
neurosensory toxicity, vomiting,
and HFS; compared with Mayo,
XELOX associated with fewer
grade 3/4 heme AEs and more
grade 3/4 GI AEs; compared
with RP, XELOX associated
with fewer grade 3/4 GI AEs and
more grade 3/4 hematologic
AEs; higher rate of grade 3/4
neurosensory toxicity and grade
3 HFS with XELOX; treatment-
related mortality at 28 days from
last study dose: 0.6% in both the
groups
AEs adverse events, B bevacizumab, bid twice a day, C capecitabine, CRC colorectal cancer, HFS hand foot syndrome, 5-FU fluorouracil,
GI gastrointestinal, HFS hand-foot syndrome, IV intravenous, LV leucovorin, Ox oxaliplatin, OS overall survival, RP Roswell Park regimen,
X-ACT Xeloda in Adjuvant Colon Cancer Therapy, XELOX capecitabine plus oxaliplatin
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capecitabine plus oxaliplatin demonstrated fewer grade 3/4
gastrointestinal AEs and more grade 3/4 hematologic AEs.
As expected, grade 3/4 neurosensory toxicity and grade 3
HFS were higher with capecitabine plus oxaliplatin. It was
concluded that capecitabine plus oxaliplatin has a man-
ageable tolerability profile in the adjuvant setting [58]. The
3-year DFS, as reported at the 2009 European Cancer
Conference, demonstrated 71% 3-year DFS for patients on
the XELOX arm, compared with 67% for the 5-FU/LV arm
(hazard ratio = 0.80; P = 0.0045) [59]. In addition, an
update presented at the 2010 Gastrointestinal Cancers
Symposium demonstrated that these differences in DFS
demonstrated similar advantage for XELOX over 5-FU/LV
for both patients[70 years and\70 years of age [60]. It is
too early to detect a survival difference, and further follow-
up is needed. These data demonstrate that XELOX can be
considered as an acceptable alternative for patients with
resectable stage III CRC in the adjuvant setting. There are
no comparative studies between XELOX, infusional 5-FU,
and oxaliplatin available at this date.
Pharmacoeconomics and patient considerations
Cost comparisons of capecitabine monotherapy versus
bolus 5-FU/LV (Mayo Clinic regimen) show that the
higher acquisition cost of capecitabine is partially or
completely offset by costs associated with treating toxicity
and the higher administration costs of IV 5-FU/LV in both
the metastatic [61, 62] and adjuvant [63–66] settings.
Cost analyses of XELOX (± bevacizumab) versus
FOLFOX (± bevacizumab) show the same trends. A
comparison of the expected costs of XELOX and FOL-
FOX-4 from the United States third-party payer and soci-
etal perspectives during the study period of the randomized
NO16966 phase III trial showed that patients receiving
FOLFOX-4 required approximately 15–20 more office
visits for drug administration and spent more hours in
office and clinic visits than patients treated with XELOX
(22–27 vs. 7–9 visits). The total direct medical costs were
comparable between XELOX and FOLFOX-4 [67, 68].
A cost-minimization analysis found that the average cost
of chemotherapy per cycle per patient was significantly
lower with capecitabine plus oxaliplatin than with FOL-
FOX-6. In addition, the analysis determined that overall
clinic/hospital resource consumption was markedly
reduced compared with FOLFOX-6 [69]. Finally, a retro-
spective database analysis reported a substantial savings
associated with capecitabine plus oxaliplatin compared
with 5-FU/LV/oxaliplatin chemotherapy [70]. Together,
these prospective pharmacoeconomic and cost analyses,
along with the retrospective claims database analysis,
provide a consistent view that capecitabine-based therapy
is associated with a favorable cost comparison versus
infusional 5-FU-based therapy in patients with CRC.
Available quality-of-life data suggest that there are no
differences between capecitabine and 5-FU-based regimens
[71, 72]. A study by Liu et al. [73] suggests that patients
prefer oral chemotherapy, provided that efficacy is not
compromised. Formal patient preference studies suggest
that oral capecitabine is preferred over IV 5-FU regimens
and that patient preference is influenced by tolerability as
well as route of administration [74, 75]. Even though oral
chemotherapy comes with advantages such as reduced
frequency of clinic visits, flexibility of taking it at home
and increased control/participation in care, it does come
with disadvantages such as compliance, need for extensive
patient education and awareness of bioavailability and drug
interactions [76].
Patients find oral chemotherapy more convenient than
IV therapy [77]. In terms of convenience, XELOX requires
fewer planned office visits than FOLFOX-4 or FOLFOX-6,
because oxaliplatin is administered every 3 weeks and
capecitabine is taken orally. Medical resource use data
from the NO16966 trial demonstrated that the need for
drug administration visits and central venous access are
reduced with XELOX versus FOLFOX-4 despite the
addition of IV agents, e.g., oxaliplatin and bevacizumab
[70]. Functional Assessment of Chronic Illness Therapy
Chemotherapy Convenience and Satisfaction Question-
naire data from the ML16987 trial showed that patients
treated with capecitabine plus oxaliplatin waste less of their
free time and are more likely to be satisfied with treatment
[71].
Future directions
Another common use of capecitabine is with radiation
therapy in the preoperative management of rectal cancer.
There are several phase II trials supporting its role in this
setting [78, 79]. We await the results of a phase III study of
preoperative chemo radiotherapy comprising radiation and
either capecitabine or 5-FU with or without oxaliplatin in
patients with resectable rectal cancer. This trial has
recently completed accrual, and results should help to
define capecitabine’s role in this setting [80].
Conclusions
The evolution of fluorpyrimidine regimens and the
introduction of new cytotoxic and targeted agents have
led to important changes in how CRC is treated. Single-
agent capecitabine, an oral pro-drug of 5-FU, has been
shown to be equivalent to IV 5-FU in mCRC as well as
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in the adjuvant setting. Capecitabine combined with
oxaliplatin also has proven to be as effective as oxa-
liplatin 5-FU-containing combinations in the treatment of
mCRC. The primary distinction between the two regi-
mens is related to differences in toxicity and ease of
administration. Capecitabine plus irinotecan combinations
in this setting have produced more variable results, with
some dose regimens resulting in excessive toxicity. At
this time, combination treatment with irinotecan and
capecitabine generally is not recommended, though there
are recent data (without celecoxib) that have been more
promising.
In addition, based on recent positive phase III data,
capecitabine in combination with oxaliplatin appears to be
an acceptable treatment option for patients in the surgical
adjuvant setting. These data were recently presented at two
international meetings and approval is expected later in the
year [58, 59]. The use of capecitabine in conjunction with
radiation therapy for the treatment of rectal cancer awaits
the results of a definitive phase III trial to further define its
role in this setting.
The choice of capecitabine over IV 5-FU primarily is
based on differences in toxicity and ease of administra-
tion. In general, there is less stomatitis and neutropenia
with capecitabine-containing regimens, with the trade-off
of more HFS reactions and diarrhea. Using capecitabine
in combination therapy avoids the use of long-term
indwelling catheters, infusion pumps, and their compli-
cations, and requires fewer patient visits to the clinic. In
terms of direct costs, capecitabine plus oxaliplatin
appears to be cost-neutral compared with 5-FU/LV/oxa-
liplatin. However, capecitabine plus oxaliplatin is asso-
ciated with improved indirect costs and patient
convenience, which may improve patient compliance and
satisfaction with treatment. Capecitabine is an acceptable
alternative to IV 5-FU in the treatment of CRC in most
settings. The primary exceptions would be in combina-
tion with irinotecan, in which case less toxicity is
observed with infusion of 5-FU as opposed to capectia-
bine. The other exception would be in the case of
patients on long-term anticoagulation with warfarin—the
intermittent schedule utilized with capecitabine and its
interaction with warfarin can cause difficulty with
maintaining safe and effective anticoagulation.
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